Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 4
Submit an article Journal homepage
153
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up

Emilia ScalzulliDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Gioia ColafigliDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Sara PepeDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Giulia De LucaDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Alessio Di PrimaDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Fabio EfficaceDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Daniela DiverioDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Roberto LatagliataDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Maurizio MartelliDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy
,
Robin FoàDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy
&
Massimo BrecciaDepartment of Translational and Precision Medicine, Sapienza University, Rome, ItalyCorrespondence[email protected]
 show all
Pages 1026-1027 | Received 18 Apr 2020, Accepted 04 Aug 2020, Published online: 16 Aug 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
"Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up." Leukemia & Lymphoma, 62(4), pp. 1026–1027

Author contributions

ES, MB the manuscript wrote and analyze the data; GC and DD performed molecular analyses; SP, GDL, ADP, RL followed patients and collected data; FE, MM and RF revised the final paper.

Disclosure statement

MB received honoraria from Novartis, Pfizer, Incyte. All the other authors have no conflict of interests.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.